Syngene outlines growth strategy in clinical trials market

Syngene International Limited announced a deal in Q2 FY26 for its first global phase III clinical trial with a U.S.-based biotech company, recruiting patients across clinical sites in India and the U.S. This reflects the company's expanding capabilities in the global clinical trials market. The overall CRDMO market is projected to grow at a 9% CAGR, reaching $330 bn by 2029, with clinical CROs contributing approximately 30% and growing at a double-digit rate.

The Indian clinical CRO market is expected to grow at a 16% CAGR from 2024-2028, outpacing the global rate of 11%. Key growth drivers include a large and diverse patient pool, availability of a skilled workforce, a reliable regulatory environment, and significant cost advantages. Syngene's T&CR business, now part of its research business segment, offers comprehensive services including human pharmacology, clinical trial services, bioanalytical services, central lab services, and allied services, supported by a 190-bed unit and 12-bed ICU.

Syngene's strategic focus for its T&CR business involves supporting complex modalities, integrating into subsequent clinical trial phases, and acting as a comprehensive clinical partner. The company emphasizes its extensive experience in BA/BE studies, integrated platform, global clinical trial management, and adherence to global compliance standards, positioning it to capitalize on growth in the APAC region.